Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carteolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 8/20 | 1.00 |
| ▸ | ADRB2 known ✓ | P07550 | 8/20 | 1.00 |
| ▸ | ADRB3 known ✓ | P13945 | 2/20 | 0.62 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carteolol SCHEMBL24811 | 1.00 | ADRB1 (1.00) | ADRB1ADRB2HTR1AOPRK1SLC6A4 | |
| Carteolol SCHEMBL2549082 | 1.00 | ADRB1 (1.00) | ADRB1ADRB2HTR1AOPRK1SLC6A4 | |
| Carteolol SCHEMBL24810 | 1.00 | ADRB1 (1.00) | ADRB1ADRB2HTR1AOPRK1SLC6A4 | |
| Carteolol SCHEMBL30872857 | 1.00 | ADRB1 (1.00) | ADRB1ADRB2HTR1AOPRK1SLC6A4 | |
| Carteolol SCHEMBL146637 | 1.00 | ADRB1 (1.00) | ADRB1ADRB2HTR1AOPRK1SLC6A4 | |
| Carteolol SCHEMBL41380 | 0.99 | ADRB2 (0.98) | ADRB1ADRB2HTR1AOPRK1SLC6A4 | |
| Carteolol SCHEMBL26664802 | 0.99 | ADRB1 (0.98) | ADRB1ADRB2HTR1AOPRK1SLC6A4 | |
| Carteolol SCHEMBL41382 | 0.99 | ADRB2 (0.98) | ADRB1ADRB2HTR1AOPRK1SLC6A4 | |
| Carteolol SCHEMBL29506901 | 0.99 | ADRB2 (0.98) | ADRB1ADRB2HTR1AOPRK1SLC6A4 | |
| Carteolol SCHEMBL26664799 | 0.99 | ADRB1 (0.98) | ADRB1ADRB2HTR1AOPRK1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027105-A1 | COMPOUND MEDICINE COMPOSITION FOR TREATING GLAUCOMA AND USE OF SAME | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2026-01-29 | — | — | US | claimed |
| EP-4527387-A1 | COMPOUND PHARMACEUTICAL COMPOSITION FOR TREATING GLAUCOMA AND USE THEREOF | Shenyang Pharmaceutical University (CN) | 2025-03-26 | — | — | EP | claimed |
| CN-114796219-B | Compound pharmaceutical composition for treating glaucoma and application thereof | 沈阳药科大学 | 2024-08-20 | — | — | CN | claimed |
| WO-2023221852-A1 | COMPOUND PHARMACEUTICAL COMPOSITION FOR TREATING GLAUCOMA AND USE THEREOF | 沈阳药科大学 | 2023-11-23 | — | — | WO | claimed |
| CN-114796219-A | Compound pharmaceutical composition for treating glaucoma and application thereof | 沈阳药科大学 | 2022-07-29 | — | — | CN | claimed |
| CN-119868367-A | Bigeminal compound pharmaceutical composition for treating glaucoma and application thereof | 宁夏康亚药业股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-115463130-A | Ophthalmic pharmaceutical composition with improved preservative efficacy or photostability | 大塚制药株式会社 | 2022-12-13 | — | — | CN | disclosed |
| CN-115444849-A | Ophthalmic pharmaceutical composition with improved preservative efficacy or photostability | 大塚制药株式会社 | 2022-12-09 | — | — | CN | disclosed |
| US-20220280607-A1 | Treatment of Heart Defects and Conditions in Pediatric Patients | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2022-09-08 | — | — | US | disclosed |
| CN-109641059-B | Ophthalmic pharmaceutical composition with improved preservative efficacy or photostability | 大塚制药株式会社 | 2022-08-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027105-A1 | COMPOUND MEDICINE COMPOSITION FOR TREATING GLAUCOMA AND USE OF SAME | PTGIR, ADRB1, ADRB2 | ADRB1 2/4885ADRB2 3/4885ADRB3 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.